Literature DB >> 27072377

Diagnostic and therapeutic potential of microRNAs in neuropsychiatric disorders: Past, present, and future.

Begum Alural1, Sermin Genc1, Stephen J Haggarty2.   

Abstract

Neuropsychiatric disorders are common health problems affecting approximately 1% of the population. Twin, adoption, and family studies have displayed a strong genetic component for many of these disorders; however, the underlying pathophysiological mechanisms and neural substrates remain largely unknown. Given the critical need for new diagnostic markers and disease-modifying treatments, expanding the focus of genomic studies of neuropsychiatric disorders to include the role of non-coding RNAs (ncRNAs) is of growing interest. Of known types of ncRNAs, microRNAs (miRNAs) are 20-25-nucleotide, single-stranded, molecules that regulate gene expression through post-transcriptional mechanisms and have the potential to coordinately regulate complex regulatory networks. In this review, we summarize the current knowledge on miRNA alteration/dysregulation in neuropsychiatric disorders, with a special emphasis on schizophrenia (SCZ), bipolar disorder (BD), and major depressive disorder (MDD). With an eye toward the future, we also discuss the diagnostic and prognostic potential of miRNAs for neuropsychiatric disorders in the context of personalized treatments and network medicine. Copyright Â
© 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bipolar disorder; MiRNA; Neuroplasticity; Non-coding RNA; Schizophrenia

Mesh:

Substances:

Year:  2016        PMID: 27072377      PMCID: PMC5292013          DOI: 10.1016/j.pnpbp.2016.03.010

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  167 in total

Review 1.  The widespread regulation of microRNA biogenesis, function and decay.

Authors:  Jacek Krol; Inga Loedige; Witold Filipowicz
Journal:  Nat Rev Genet       Date:  2010-07-27       Impact factor: 53.242

Review 2.  Exosomes: Natural Carriers for siRNA Delivery.

Authors:  Lalit Kumar; Shivani Verma; Bhuvaneshwar Vaidya; Vivek Gupta
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

Review 3.  Pathophysiology and therapeutic potential of purinergic signaling.

Authors:  Geoffrey Burnstock
Journal:  Pharmacol Rev       Date:  2006-03       Impact factor: 25.468

4.  Genetic variants and abnormal processing of pre-miR-182, a circadian clock modulator, in major depression patients with late insomnia.

Authors:  Ester Saus; Virginia Soria; Geòrgia Escaramís; Francesca Vivarelli; José M Crespo; Birgit Kagerbauer; José Manuel Menchón; Mikel Urretavizcaya; Mònica Gratacòs; Xavier Estivill
Journal:  Hum Mol Genet       Date:  2010-07-23       Impact factor: 6.150

5.  Evaluation of six SNPs of MicroRNA machinery genes and risk of schizophrenia.

Authors:  Yi Zhou; Jun Wang; Xiaojun Lu; Xingbo Song; Yuanxin Ye; Juan Zhou; Binwu Ying; Lanlan Wang
Journal:  J Mol Neurosci       Date:  2012-09-27       Impact factor: 3.444

6.  Circuit- and Diagnosis-Specific DNA Methylation Changes at γ-Aminobutyric Acid-Related Genes in Postmortem Human Hippocampus in Schizophrenia and Bipolar Disorder.

Authors:  W Brad Ruzicka; Sivan Subburaju; Francine M Benes
Journal:  JAMA Psychiatry       Date:  2015-06       Impact factor: 21.596

7.  Comparison of plasma MicroRNA levels in drug naive, first episode depressed patients and healthy controls.

Authors:  Mehmet Akif Camkurt; Şenel Acar; Salih Coşkun; Mehmet Güneş; Serkan Güneş; Mehmet Fatih Yılmaz; Ayşegül Görür; Lülüfer Tamer
Journal:  J Psychiatr Res       Date:  2015-07-23       Impact factor: 4.791

8.  DNA methylation analysis of BDNF gene promoters in peripheral blood cells of schizophrenia patients.

Authors:  Tempei Ikegame; Miki Bundo; Fumiko Sunaga; Tatsuro Asai; Fumichika Nishimura; Akane Yoshikawa; Yoshiya Kawamura; Hiroyuki Hibino; Mamoru Tochigi; Chihiro Kakiuchi; Tsukasa Sasaki; Tadafumi Kato; Kiyoto Kasai; Kazuya Iwamoto
Journal:  Neurosci Res       Date:  2013-08-22       Impact factor: 3.304

9.  Impact of a microRNA MIR137 susceptibility variant on brain function in people at high genetic risk of schizophrenia or bipolar disorder.

Authors:  Heather C Whalley; Martina Papmeyer; Liana Romaniuk; Emma Sprooten; Eve C Johnstone; Jeremy Hall; Stephen M Lawrie; Kathryn L Evans; Hilary P Blumberg; Jessika E Sussmann; Andrew M McIntosh
Journal:  Neuropsychopharmacology       Date:  2012-08-01       Impact factor: 7.853

10.  Ankyrin-G regulates neurogenesis and Wnt signaling by altering the subcellular localization of β-catenin.

Authors:  O Durak; F C de Anda; K K Singh; M P Leussis; T L Petryshen; P Sklar; L-H Tsai
Journal:  Mol Psychiatry       Date:  2014-05-13       Impact factor: 15.992

View more
  18 in total

1.  Epigenetic signature for attention-deficit/hyperactivity disorder: identification of miR-26b-5p, miR-185-5p, and miR-191-5p as potential biomarkers in peripheral blood mononuclear cells.

Authors:  Cristina Sánchez-Mora; María Soler Artigas; Iris Garcia-Martínez; Mireia Pagerols; Paula Rovira; Vanesa Richarte; Montse Corrales; Christian Fadeuilhe; Natàlia Padilla; Xavier de la Cruz; Barbara Franke; Alejandro Arias-Vásquez; Miguel Casas; Josep-Antoni Ramos-Quiroga; Marta Ribasés
Journal:  Neuropsychopharmacology       Date:  2018-12-19       Impact factor: 7.853

Review 2.  Dysregulation of miRNA and its potential therapeutic application in schizophrenia.

Authors:  Ting Cao; Xue-Chu Zhen
Journal:  CNS Neurosci Ther       Date:  2018-03-12       Impact factor: 5.243

Review 3.  Plant and Animal microRNAs (miRNAs) and Their Potential for Inter-kingdom Communication.

Authors:  Yuhai Zhao; Lin Cong; Walter J Lukiw
Journal:  Cell Mol Neurobiol       Date:  2017-09-06       Impact factor: 5.046

Review 4.  MicroRNAs as biomarker and novel therapeutic target for posttraumatic stress disorder in Veterans.

Authors:  Sudhiranjan Gupta; Rakeshwar S Guleria; Yvette Z Szabo
Journal:  Psychiatry Res       Date:  2021-10-26       Impact factor: 3.222

Review 5.  miRNAs as potential diagnostic biomarkers and pharmacogenomic indicators in psychiatric disorders.

Authors:  Evangelia Eirini Tsermpini; Christina I Kalogirou; George C Kyriakopoulos; George P Patrinos; Constantinos Stathopoulos
Journal:  Pharmacogenomics J       Date:  2022-06-20       Impact factor: 3.245

Review 6.  Mapping the Schizophrenia Genes by Neuroimaging: The Opportunities and the Challenges.

Authors:  Ayla Arslan
Journal:  Int J Mol Sci       Date:  2018-01-11       Impact factor: 5.923

7.  Microbial regulation of microRNA expression in the amygdala and prefrontal cortex.

Authors:  Alan E Hoban; Roman M Stilling; Gerard M Moloney; Rachel D Moloney; Fergus Shanahan; Timothy G Dinan; John F Cryan; Gerard Clarke
Journal:  Microbiome       Date:  2017-08-25       Impact factor: 14.650

Review 8.  Animal models to improve our understanding and treatment of suicidal behavior.

Authors:  T D Gould; P Georgiou; L A Brenner; L Brundin; A Can; P Courtet; Z R Donaldson; Y Dwivedi; S Guillaume; I I Gottesman; S Kanekar; C A Lowry; P F Renshaw; D Rujescu; E G Smith; G Turecki; P Zanos; C A Zarate; P A Zunszain; T T Postolache
Journal:  Transl Psychiatry       Date:  2017-04-11       Impact factor: 6.222

9.  The microbiome regulates amygdala-dependent fear recall.

Authors:  A E Hoban; R M Stilling; G Moloney; F Shanahan; T G Dinan; G Clarke; J F Cryan
Journal:  Mol Psychiatry       Date:  2017-05-16       Impact factor: 15.992

10.  An Ontology Systems Approach on Human Brain Expression and Metaproteomics.

Authors:  Adolfo Flores Saiffe Farías; Adriana P Mendizabal; J Alejandro Morales
Journal:  Front Microbiol       Date:  2018-03-08       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.